Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and ‘bridge’ to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgment

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

PK: responsible for study design, extracting and analyzing data, interpreting results, updating reference lists and creating the summary of findings and writing the manuscript. MAZ: contributed to data collection, analyzing data and results and provided feedback on the manuscript. MAD: contributed to the design of the study, data analysis and results interpretation and provided feedback on the manuscript. MAB: contributed to data collection, analyzing data and results and provided feedback on the manuscript. AAG: evaluated all the tissue blocks and confirmed disease diagnosis and provided feedback on the manuscript. AAN: evaluated the imaging tests and assessed the disease burden prior and after chemotherapy and provided feedback on the manuscript. HAH: contributed to the design of the study, results interpretation and provided feedback on the manuscript. SK: contributed to the design of the study, and provided feedback on the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.